Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
Public ClinicalTrials.gov record NCT00531947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible Dose Study of the Safety and Efficacy of EMSAM in Adolescents With Major Depression
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of adolescents (aged 12 through 17 years) with Major Depressive Disorder (MDD).
Study identification
- NCT ID
- NCT00531947
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 308 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2007
- Primary completion
- Sep 30, 2010
- Completion
- Sep 30, 2010
- Last update posted
- Jan 14, 2014
2007 – 2010
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dr. Nelson Handal | Dothan | Alabama | — | — |
| Dr. Mohammed Bari | National City | California | — | — |
| Dr. Michael McManus | San Diego | California | — | — |
| Dr. Elias Sarkis | Gainesville | Florida | — | — |
| Dr. Scott Segal | North Miami | Florida | — | — |
| Dr. Mary Stedman | Tampa | Florida | — | — |
| Dr. Irving Kolin | Winter Park | Florida | — | — |
| Dr. Rory Murphy | Overland Park | Kansas | — | — |
| Dr. Andrew Sediloo | Owensboro | Kentucky | — | — |
| Dr. Bruce Waslick | Springfield | Massachusetts | — | — |
| Dr. Christopher Kratochvil | Omaha | Nebraska | — | — |
| Dr. Ann Childress | Las Vegas | Nevada | — | — |
| Dr. Melissa DelBello | Cincinnati | Ohio | — | — |
| Dr. Leland Dennis | Oklahoma City | Oklahoma | — | — |
| Dr. David Brown | Austin | Texas | — | — |
| Dr. Alain Katic | Bellaire | Texas | — | — |
| Dr. Graham Emslie | Dallas | Texas | — | — |
| Dr. Mary Shemo | Charlottesville | Virginia | — | — |
| Dr. John Gilliam | Richmond | Virginia | — | — |
| Dr. Arifulla Khan | Bellevue | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00531947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 14, 2014 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00531947 live on ClinicalTrials.gov.